Search

Your search keyword '"Azedra (Medication)"' showing total 23 results
Start Over Descriptor "Azedra (Medication)" Publisher comtex news network, inc.
23 results on '"Azedra (Medication)"'

1. Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

Subjects
Progenics Pharmaceuticals Inc. -- International economic relations, Pharmaceutical industry -- International economic relations, Insurance industry, Finance, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, May 07, May 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a [...]

Published
2020

2. PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Finance, Company earnings/profit, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, March 13, Mar 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. 'The recent positive [...]

Published
2020

3. Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc., Pharmaceutical industry -- International economic relations, Stockholders, Pipelines, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, Nov 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter 2019. [...]

Published
2019

4. Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Subjects
United States. Food and Drug Administration -- Officials and employees, Bayer AG -- Officials and employees, Progenics Pharmaceuticals Inc. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, Aug 09, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL(F-DCFPyL); Topline Data Expected by Year End 2019 [...]

Published
2019

5. CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA(R) (iobenguane I 131)

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Medical care quality, Pharmaceutical industry -- Forecasts and trends, Prospective payment systems (Medical care) -- Innovations -- Usage, Methylnaltrexone, Technology, Medicaid, Beneficiaries, Medicare, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, Aug 06, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, [...]

Published
2019

6. Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Novartis Pharma AG -- Forecasts and trends, Vice presidents (Organizations), Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, July 08, Jul 08, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and [...]

Published
2019

7. Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote 'FOR' ALL of Progenics' Director Nominees

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc. -- Forecasts and trends, Stockholders, Corporate governance, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Proxy, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, July 01, Jul 01, 2019 (GLOBE NEWSWIRE via COMTEX) -- Glass Lewis Believes Velan's 'Fundamental Operational and Corporate Governance Case Fails to Bear Fruit' Glass Lewis Agrees the [...]

Published
2019

8. Progenics Reiterates Targeted Directors' Indispensable Experience and Leadership Critical to the Company's Long-Term Success

Subjects
United States. Securities and Exchange Commission -- Officials and employees, Institutional Shareholder Services -- Forecasts and trends -- Officials and employees, Progenics Pharmaceuticals Inc. -- Forecasts and trends -- Officials and employees, Pharmaceutical industry -- Forecasts and trends -- Officials and employees, Methylnaltrexone, Stockholders, Artificial intelligence, Proxy, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 28, Jun 28, 2019 (GLOBE NEWSWIRE via COMTEX) -- Comments on ISS Report Urges Shareholders to Vote 'FOR' All of the Company's Qualified Directors on the WHITE [...]

Published
2019

9. Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan's Latest Inaccurate Claims

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Stockholders, Artificial intelligence, Proxy, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 24, Jun 24, 2019 (GLOBE NEWSWIRE via COMTEX) -- Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan's Baseless Criticisms [...]

Published
2019

10. Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA(R) (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors

Subjects
United States. Food and Drug Administration -- Planning, Progenics Pharmaceuticals Inc. -- Forecasts and trends -- Planning, Business planning, Neuroendocrine tumors -- Care and treatment, Drugs -- Planning, Tumors -- Care and treatment, Pharmaceutical industry -- Forecasts and trends -- Planning, Respiratory system agents, Cancer, Cancer metastasis, Artificial intelligence, Company business planning, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 20, Jun 20, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ('Progenics' or the 'Company'), an oncology company developing innovative targeted medicines and artificial intelligence [...]

Published
2019

11. Progenics to Mail Letter to Shareholders

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc. -- Forecasts and trends, Novartis AG -- Forecasts and trends, Stockholders, Pamidronate, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Cancer, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 13, Jun 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ('Progenics' or the 'Company'), an oncology company developing innovative targeted medicines and artificial intelligence [...]

Published
2019

12. Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Professional associations, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Technology, Drugs, Associations, Cancer, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 06, Jun 06, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and [...]

Published
2019

13. Progenics Announces Updated Survival Data for AZEDRA(R) (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Pheochromocytoma, Artificial intelligence, Professional associations, Market trend/market analysis, Banking, finance and accounting industries, Business, American Society of Clinical Oncology, Azedra (Medication)
Abstract

NEW YORK, June 03, Jun 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- - Long-Term Follow Up Data from Pivotal Study Presented at ASCO - - Patients Treated with AZEDRA Show [...]

Published
2019

14. Progenics Pharmaceuticals Mails Letter to Shareholders

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc., Stockholders, Pharmaceutical industry, Cancer, Artificial intelligence, Proxy, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, June 03, Jun 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- Asks Shareholders to Vote 'FOR' All the Company's Qualified Directors on the WHITE Proxy Card Progenics Pharmaceuticals, Inc. [...]

Published
2019

15. Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Professional associations, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Associations, Cancer, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, American Society of Clinical Oncology, Azedra (Medication)
Abstract

NEW YORK, May 23, May 23, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and [...]

Published
2019

16. Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

Subjects
Progenics Pharmaceuticals Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, May 09, May 09, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2019 and provided a business update. [...]

Published
2019

17. Progenics Pharmaceuticals Issues Statement Regarding Velan Capital

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Methylnaltrexone, Stockholders, Corporate directors, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, May 06, May 06, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed [...]

Published
2019

18. Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc. -- Company sales and earnings, Bayer AG -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, March 14, Mar 14, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2018 and provided a [...]

Published
2019

19. Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA(R) (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting

Subjects
Progenics Pharmaceuticals Inc. -- Conferences, meetings and seminars -- Forecasts and trends, Pharmaceutical industry -- Conferences, meetings and seminars -- Forecasts and trends, Methylnaltrexone -- Conferences, meetings and seminars, Associations, Cancer, Cancer patients, Clinical trials, Technology, Drugs, Market trend/market analysis, Banking, finance and accounting industries, Business, Endocrine Society -- Conferences, meetings and seminars, Azedra (Medication)
Abstract

NEW YORK, March 11, Mar 11, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating [...]

Published
2019

20. Progenics Acquires AZEDRA(R) (iobenguane I 131) Radiopharmaceutical Manufacturing Facility

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Forecasts and trends -- Mergers, acquisitions and divestments, Pheochromocytoma, Market trend/market analysis, Company acquisition/merger, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, Feb 11, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]

Published
2019

21. Progenics Announces Publication of Pivotal Trial of AZEDRA(R) (iobenguane I 131) in The Journal of Nuclear Medicine

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Cancer treatment, Drugs, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, Oct 09, 2018 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]

Published
2018

22. Progenics Announces Addition of AZEDRA(R) (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends -- Technology application, Cancer treatment -- Technology application, Cancer -- Drug therapy -- Technology application, Pharmaceutical industry -- Forecasts and trends -- Technology application, Drug approval -- Technology application, Market trend/market analysis, Technology application, Banking, finance and accounting industries, Business, National Comprehensive Cancer Network -- Technology application, Azedra (Medication)
Abstract

NEW YORK, Sep 17, 2018 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]

Published
2018

23. Progenics Pharmaceuticals Announces FDA Approval for AZEDRA(R) (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc., Metastasis -- Drug therapy, Pheochromocytoma -- Drug therapy, Drug approval, Children -- Health aspects, Pharmaceutical industry, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, July 30, Jul 30, 2018 (GLOBE NEWSWIRE via COMTEX) -- The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results